WO2001032211A3 - Conjugate compounds for treating atheroma and other diseases - Google Patents

Conjugate compounds for treating atheroma and other diseases Download PDF

Info

Publication number
WO2001032211A3
WO2001032211A3 PCT/US2000/029524 US0029524W WO0132211A3 WO 2001032211 A3 WO2001032211 A3 WO 2001032211A3 US 0029524 W US0029524 W US 0029524W WO 0132211 A3 WO0132211 A3 WO 0132211A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
atheroma
conjugate compounds
treating
compounds
Prior art date
Application number
PCT/US2000/029524
Other languages
French (fr)
Other versions
WO2001032211A2 (en
Inventor
Jonathan L Sessler
Darren Madga
Original Assignee
Pharmacyclics Inc
Univ Texas
Jonathan L Sessler
Darren Madga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc, Univ Texas, Jonathan L Sessler, Darren Madga filed Critical Pharmacyclics Inc
Priority to AU12340/01A priority Critical patent/AU1234001A/en
Priority to EP00973891A priority patent/EP1223982A2/en
Publication of WO2001032211A2 publication Critical patent/WO2001032211A2/en
Publication of WO2001032211A3 publication Critical patent/WO2001032211A3/en
Priority to US10/160,205 priority patent/US20030031676A1/en
Priority to HK03100643.8A priority patent/HK1050315A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines

Abstract

Disclosed are compounds which are conjugates of (a) a moiety capable of localizing in the cells of a tumor or atheroma and (b) a moiety capable of catalyzing the production of reactive oxygen species from a cellular metabolite. The disclosed compounds which are useful for treating atheroma, tumors and other neoplastic tissue.
PCT/US2000/029524 1999-10-29 2000-10-27 Conjugate compounds for treating atheroma and other diseases WO2001032211A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU12340/01A AU1234001A (en) 1999-10-29 2000-10-27 Conjugate compounds for treating atheroma, tumors and other neoplastic tissue
EP00973891A EP1223982A2 (en) 1999-10-29 2000-10-27 Conjugate for treating atheroma and other diseases
US10/160,205 US20030031676A1 (en) 1999-10-29 2002-05-30 Conjugate compounds for treating atheroma and other diseases
HK03100643.8A HK1050315A1 (en) 1999-10-29 2003-01-24 Conjugate for treating atheroma and other diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43129899A 1999-10-29 1999-10-29
US09/431,298 1999-10-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/160,205 Continuation US20030031676A1 (en) 1999-10-29 2002-05-30 Conjugate compounds for treating atheroma and other diseases

Publications (2)

Publication Number Publication Date
WO2001032211A2 WO2001032211A2 (en) 2001-05-10
WO2001032211A3 true WO2001032211A3 (en) 2002-03-07

Family

ID=23711325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029524 WO2001032211A2 (en) 1999-10-29 2000-10-27 Conjugate compounds for treating atheroma and other diseases

Country Status (4)

Country Link
EP (1) EP1223982A2 (en)
AU (1) AU1234001A (en)
HK (1) HK1050315A1 (en)
WO (1) WO2001032211A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201610306RA (en) * 2014-06-11 2017-01-27 Univ Texas Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587371A (en) * 1992-01-21 1996-12-24 Pharmacyclics, Inc. Texaphyrin-oligonucleotide conjugates
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
WO1999062551A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
WO2001032210A2 (en) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587371A (en) * 1992-01-21 1996-12-24 Pharmacyclics, Inc. Texaphyrin-oligonucleotide conjugates
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
WO1999062551A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
WO2001032210A2 (en) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue

Also Published As

Publication number Publication date
AU1234001A (en) 2001-05-14
WO2001032211A2 (en) 2001-05-10
EP1223982A2 (en) 2002-07-24
HK1050315A1 (en) 2003-06-20

Similar Documents

Publication Publication Date Title
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
EP2348024A3 (en) Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
WO2001091798A3 (en) Tumor activated prodrug compounds
WO1999043355A3 (en) Formulations containing oxaliplatin
AU2001227966A1 (en) Methods for treating tumors
EP2289940A3 (en) Treatment of metastatic disease
EP2062918A3 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
AU2001255602A1 (en) Methods for treating bone tumors
AU7380500A (en) Methods for treating tumors using neutron therapy
WO2000066528A3 (en) Quinones for treatment of diseases
WO2002036601A3 (en) Phase transfer catalyzed glycosidation of an indolocarbazole
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
WO2002043773A3 (en) Tissue specific prodrugs
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001032211A3 (en) Conjugate compounds for treating atheroma and other diseases
AU6969098A (en) 1,2,4-benzotriazine oxides formulations
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
WO2003078607A3 (en) Tissue specific signal-plexes to dedifferentiate and redifferentiate cells
AU2002224096A1 (en) Method of testing anticancer agent-sensitivity of tumor cells
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
WO2005016958A3 (en) Compounds for treating tumors
AU2607999A (en) Sustained release implant, methods for preparation thereof and for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000973891

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10160205

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000973891

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000973891

Country of ref document: EP